A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
about
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaConditioning regimens for hematopoietic cell transplantation: one size does not fit allComparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab eraThe potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
P2860
Q33792160-2DC30477-9C66-4660-A810-F8315DE596F8Q33917170-C7D039E7-FA2D-45B3-9012-B4B8C50119F4Q35151998-BA174396-69FD-4CC3-9042-8DABEE8B9629Q35231363-CD750024-4FBB-4696-9397-E87E9C28A0B3Q36264895-94DAD508-D02B-4F45-B8FA-A8542CCF36A6Q37071972-75B2FBDE-22E6-437F-A848-6A6894EDFBB9Q37312857-8FADD165-18A7-487F-961A-DFAF3AC44148Q38392246-5DBB465F-17A1-4332-90E0-5C4F7ADC6B5BQ39307476-A2F40040-F242-486D-B8CD-322A873B7C03Q47142550-6EB64A7C-089C-46B2-BC65-EC372E2E76B6Q48573554-B0423EEB-1038-4878-8029-52B2AFA19C55Q52970765-39A688E1-7B11-4E34-AC63-84FF6474FB4D
P2860
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@ast
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@en
type
label
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@ast
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@en
prefLabel
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@ast
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@en
P2093
P2860
P50
P1476
A phase II study of a nonmyelo ...... al in chemosensitive patients.
@en
P2093
Ann A Jakubowski
Craig H Moskowitz
Craig S Sauter
Esperanza B Papadopoulos
Guenther Koehne
Hugo Castro-Malaspina
Jenna D Goldberg
Juliet N Barker
Junting Zheng
Lauren Lechner
P2860
P304
P356
10.1016/J.BBMT.2013.11.029
P577
2013-12-04T00:00:00Z